Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.

Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D.

Cancers (Basel). 2019 Sep 12;11(9). pii: E1355. doi: 10.3390/cancers11091355. Review.

2.

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients.

Cattrini C, Rubagotti A, Zinoli L, Cerbone L, Zanardi E, Capaia M, Barboro P, Boccardo F.

Cancers (Basel). 2019 Sep 13;11(9). pii: E1365. doi: 10.3390/cancers11091365.

3.

Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience.

Vallome G, Cattrini C, Messina C, Cerbone L, Boccardo F, Zanardi E.

Anticancer Drugs. 2019 Sep;30(8):854-858. doi: 10.1097/CAD.0000000000000805.

PMID:
31356228
4.

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone.

Zanardi E, Soldato D, Latocca MM, Cattrini C, Boccardo F.

Ther Adv Urol. 2019 Jun 11;11:1756287219854908. doi: 10.1177/1756287219854908. eCollection 2019 Jan-Dec.

5.

Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.

Cattrini C, Cerbone L, Rubagotti A, Zinoli L, Latocca MM, Messina C, Zanardi E, Boccardo F.

Clin Genitourin Cancer. 2019 Aug;17(4):e724-e732. doi: 10.1016/j.clgc.2019.03.010. Epub 2019 Mar 28.

PMID:
31160193
6.

Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.

Cattrini C, Rubagotti A, Nuzzo PV, Zinoli L, Salvi S, Boccardo S, Perachino M, Cerbone L, Vallome G, Latocca MM, Zanardi E, Boccardo F.

Clin Genitourin Cancer. 2018 Dec;16(6):e1257-e1265. doi: 10.1016/j.clgc.2018.07.019. Epub 2018 Jul 29.

PMID:
30170989
7.

CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.

Messina C, Cattrini C, Buzzatti G, Cerbone L, Zanardi E, Messina M, Boccardo F.

Breast Cancer Res Treat. 2018 Nov;172(1):9-21. doi: 10.1007/s10549-018-4901-0. Epub 2018 Jul 27.

PMID:
30054831
8.

A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.

Capaia M, Granata I, Guarracino M, Petretto A, Inglese E, Cattrini C, Ferrari N, Boccardo F, Barboro P.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1920. doi: 10.3390/ijms19071920.

9.

Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer.

Cattrini C, Zanardi E, Boccardo F.

J Clin Oncol. 2018 Aug 1;36(22):2350. doi: 10.1200/JCO.2018.78.0031. Epub 2018 Jun 1. No abstract available.

PMID:
29856689
10.

Atezolizumab and bladder cancer: facing a complex disease.

Cattrini C, Boccardo F.

Lancet. 2018 Jan 27;391(10118):305-306. doi: 10.1016/S0140-6736(18)30095-3. Epub 2018 Jan 31. No abstract available.

PMID:
29413038
11.

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.

Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Boccardo F.

Ther Adv Med Oncol. 2018 Jan 9;10:1758834017745819. doi: 10.1177/1758834017745819. eCollection 2018.

12.

Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectives.

Messina C, Buzzatti G, Dellepiane C, Cavo A, Tolomeo F, Cattrini C, Boccardo F.

Anticancer Drugs. 2016 Nov;27(10):917-43. doi: 10.1097/CAD.0000000000000405. Review.

PMID:
27400375
13.

Immunotherapy for genitourinary cancer: state of the art and new perspectives.

Cattrini C, Dellepiane C, Cavo A, Buzzatti G, Tolomeo F, Messina C, Boccardo F.

Anticancer Drugs. 2016 Aug;27(7):585-99. doi: 10.1097/CAD.0000000000000376. Review.

PMID:
27183027

Supplemental Content

Loading ...
Support Center